Biologicals

Influenza

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza vaccines containing the pandemic influenza A H1N1 (2009) virus: Update

H1N1 specific-update of TRS 941, Annex 5

Proposed Guidelines: Regulatory Preparedness for Human Pandemic Influenza Vaccines

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines

Recommendations for the production and control of influenza vaccine (inactivated)

WHO Technical Report Series, No. 927, 2005, Annex 3

Influenza vaccine, live

Title: Requirements for Influenza Vaccine (Live); Adopted 1978, TRS No 638, Annex 3

FOR PUBLIC CONSULTATION:

COMMENTS TO BE RECEIVED BY 15 JUNE 2012

NEW PUBLICATIONS

UPCOMING EVENTS

WHO Collaborating Centers on Standardization on Regulatory Evaluation of Vaccines & Biotherapeutic Products: 1st meeting, Geneva, 24-26 April 2012

WHO Workshop on implementing WHO Guidelines on evaluating similar biotherapeutic products (SBPs), Xiamen, China, 28-30 May 2012

WHO Informal Consultation on the revision of the recommendations to assure the Quality, Safety and Efficacy of biological products prepared by recombinant DNA technology, Xiamen, China, 31 May-1 June 2012

CONTACTS

Quality, Safety and Standards (QSS)
Immunization, Vaccines and Biologicals (IVB)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971